February 22, 2021 February 23, 2021 February 24, 2021 February 25, 2021 February 26, 2021

Program

52 - Master Class

Master Class: COVID-19 & hemostasis

8:30 a.m. - 9:30 a.m.

53 - Master Class

Master Class: How I treat chronic ITP in children

9:00 a.m. - 10:00 a.m.

54 - Master Class

Master Class: How I approach anemia in children

10:00 a.m. - 11:00 a.m.

55 - Master Class

Master Class: Interprofessional approach of joint health in pediatric haemophilia

11:00 a.m. - 12:00 p.m.

56 - Master Class

Master Class: Emicizumab & Coagulation lab

11:00 a.m. - 12:00 p.m.

57 - Satellite Symposium

Swedish Orphan Biovitrum AB / Florio GmbH

12:00 p.m. - 1:30 p.m.

58 - Satellite Symposium

Takeda Pharma Vertrieb GmbH & Co. KG

12:00 p.m. - 1:30 p.m.

59 - Satellite Symposium

Bayer Vital GmbH

12:00 p.m. - 1:30 p.m.

60 - Satellite Symposium

Grifols Deutschland GmbH

12:00 p.m. - 1:15 p.m.

61 - Oral Communication

Mechanisms of Disease I

1:45 p.m. - 3:15 p.m.

62 - Oral Communication

Pediatrics & Gynecology-Obstetrics

1:45 p.m. - 3:15 p.m.

63 - Oral Communication

Megakaryocytes, Platelets & VWF

1:45 p.m. - 3:15 p.m.

64 - Working Group

BDDH-Sitzung

2:00 p.m. - 3:00 p.m.

65 - Working Group

BDDH-MV

3:00 p.m. - 3:30 p.m.

66 - Plenary

Plenary 3 - Physicians Across Borders

3:30 p.m. - 4:30 p.m.

67 - State of the Art

Pediatrics

4:45 p.m. - 6:15 p.m.

68 - State of the Art

Cardiology

4:45 p.m. - 6:15 p.m.

69 - State of the Art

Procoagulant Platelets

4:45 p.m. - 6:15 p.m.

70 - State of the Art

Hemato-oncology B

4:45 p.m. - 6:15 p.m.

71 - State of the Art

New treatments

4:45 p.m. - 6:15 p.m.

72 - Miscellaneous

GTH Mitgliederversammlung

6:30 p.m. - 8:30 p.m.

Plenary

State of the Art

Oral Communication

Symposium

Workshop

Master Class

Working Group

Miscellaneous

Events

52 - Master Class

Master Class: COVID-19 & hemostasis

8:30 a.m. - 9:30 a.m., External session

Tutor: Thomas Lecompte (Geneva)

The Master Classes take place outside the congress platform, by pre-registration. The access data for the session will be sent to all registered participants a few days in advance.

52 - Master Class

Master Class: COVID-19 & hemostasis

8:30 a.m. - 9:30 a.m., External session

53 - Master Class

Master Class: How I treat chronic ITP in children

9:00 a.m. - 10:00 a.m., External session 2

Tutor: Nicolas von der Weid (Basel)

The Master Classes take place outside the congress platform, by pre-registration. The access data for the session will be sent to all registered participants a few days in advance.

53 - Master Class

Master Class: How I treat chronic ITP in children

9:00 a.m. - 10:00 a.m., External session 2

54 - Master Class

Master Class: How I approach anemia in children

10:00 a.m. - 11:00 a.m., External session

Tutor: Markus Schmugge (Zurich)

The Master Classes take place outside the congress platform, by pre-registration. The access data for the session will be sent to all registered participants a few days in advance.

54 - Master Class

Master Class: How I approach anemia in children

10:00 a.m. - 11:00 a.m., External session

55 - Master Class

Master Class: Interprofessional approach of joint health in pediatric haemophilia

11:00 a.m. - 12:00 p.m., External session

Tutor: Manuela Albisetti (Zurich), Denise Etzweiler (Zurich)

The Master Classes take place outside the congress platform, by pre-registration. The access data for the session will be sent to all registered participants a few days in advance.

55 - Master Class

Master Class: Interprofessional approach of joint health in pediatric haemophilia

11:00 a.m. - 12:00 p.m., External session

56 - Master Class

Master Class: Emicizumab & Coagulation lab

11:00 a.m. - 12:00 p.m., External session 2

Tutor: Pierre Fontana (Geneva)

The Master Classes take place outside the congress platform, by pre-registration. The access data for the session will be sent to all registered participants a few days in advance.

56 - Master Class

Master Class: Emicizumab & Coagulation lab

11:00 a.m. - 12:00 p.m., External session 2

57 - Satellite Symposium

Swedish Orphan Biovitrum AB / Florio GmbH

12:00 p.m. - 1:30 p.m., Rome

Chair: Lukas Graf (St. Gallen)

Take control – harness the power of data to aim higher

Begrüßung

Lukas Graf, St. Gallen
Medical Devices in Haemophilia: Erwartungen eines Arztes und eines Patienten

Carmen Escuriola-Ettingshausen, Mörfelden-Walldorf
Patient self-empowerment: gemeinsam personalisierte Ziele erreichen

Georg Goldmann, Bonn
Diskussion

57 - Satellite Symposium

Swedish Orphan Biovitrum AB / Florio GmbH

12:00 p.m. - 1:30 p.m., Rome

58 - Satellite Symposium

Takeda Pharma Vertrieb GmbH & Co. KG

12:00 p.m. - 1:30 p.m., Barcelona

Chair: Ingrid Pabinger-Fasching (Vienna)

Personalisierte Therapie - eine neue Ära in der Behandlung von Blutgerinnungsstörungen

PK-gesteuerte Prophylaxe – eine therapeutische Strategie zur Erhaltung der Gelenkgesundheit

Robert Klamroth, Berlin
Das Von-Willebrand-Syndrom - der personalisierte Therapieansatz mit dem rVWF

Michael Spannagl, München
Schritte zur Präzisionsmedizin in der personalisierten Therapie

Peter Turecek, Wien

58 - Satellite Symposium

Takeda Pharma Vertrieb GmbH & Co. KG

12:00 p.m. - 1:30 p.m., Barcelona

59 - Satellite Symposium

Bayer Vital GmbH

12:00 p.m. - 1:30 p.m., Sydney

Chair: Bettina Kemkes-Matthes (Gießen), Edelgard Lindhoff-Last (Frankfurt am Main)

Grenzen überwinden - Protektive Strategien bei Thrombosen und Hämophilie

Begrüßung

Bettina Kemkes-Matthes, Giessen
VTE-Patienten behandeln und schützen – Thrombosen therapieren und Rezidive vermeiden

Rupert M. Bauersachs, Darmstadt
Leitlinienempfehlungen und Patientenwunsch – Strategien zum Therapieerfolg bei tumorassoziierter Thrombembolie

Cihan Ay, Vienna
Hämophilie A - Neue Guidelines & EHLs topaktuell

Andreas Tiede, Hannover
Ask-the-Expert
Zusammenfassung

Edelgard Lindhoff-Last, Frankfurt am Main

59 - Satellite Symposium

Bayer Vital GmbH

12:00 p.m. - 1:30 p.m., Sydney

60 - Satellite Symposium

Grifols Deutschland GmbH

12:00 p.m. - 1:15 p.m., Lausanne

Chair: Axel Matzdorff (Schwedt/Oder)

Fostamatinib - die neue Therapie bei chronischer ITP ab der Zweitlinie

Einleitung

Axel Matzdorff, Schwedt/Oder
Leitlinien-Update & besondere Aspekte der ITP-Therapie unter Covid-19

Axel Matzdorff, Schwedt/Oder
Leben mit ITP: Patienten im Fokus

Rosa Sonja Alesci, Bad Homburg
Klinische Erfahrungen mit dem SYK-Inhibitor Fostamatinib

Oliver Meyer, Berlin
Diskussion

60 - Satellite Symposium

Grifols Deutschland GmbH

12:00 p.m. - 1:15 p.m., Lausanne

61 - Oral Communication

Mechanisms of Disease I

1:45 p.m. - 3:15 p.m., Rome

Chair: Debora Bertaggia Calderara (Lausanne), Dimitrios A. Tsakiris (Basel)

1
Factor Xa and factor IIa inhibitors differentially regulate inflammation in myocardial ischemia reperfusion injury

I. Gadi, S. Fatima, S. Kohli, A. Elwakiel, B. Isermann, K. Shahzad, Presenter: K. Shahzad (Leipzig)
2
von Willebrand factor (vWF) significantly modifies the sedimentation profile of FVIII-containing immune complexes (FVIII-IC) based on the type of anti-FVIII antibodies

O. Oleshko, U. Curth, A. Tiede, S. Werwitzke, Presenter: O. Oleshko (Hannover)
3
Characterization of activity and cleavage of von Willebrand disease type 2B variants

M. A. Brehm, Y. Yildiz, K. Lehmann, T. Obser, A. Mojzisch, S. Peine, S. Schneppenheim, U. Budde, R. Schneppenheim, Presenter: M. A. Brehm (Hamburg)
4
Impact of osteopontin on platelet adhesion and activation in intraluminal thrombus formation and abdominal aortic aneurysm progression

C. Böddeker, M. Wagenhäuser, W. Ibing, A. Ehrenberg, H. Schelzig, M. Elvers, Presenter: C. Böddeker (Düsseldorf)
5
WITHDRAWN - Impact of platelets and red blood cells in abdominal aortic aneurysm

K. J. Krott, M. Wagenhäuser, A. Ehrenberg, T. Feige, A. Beele, E. Schickentanz-Dey, H. Schelzig, M. Elvers, Presenter: K. J. Krott (Düsseldorf)

61 - Oral Communication

Mechanisms of Disease I

1:45 p.m. - 3:15 p.m., Rome

62 - Oral Communication

Pediatrics & Gynecology-Obstetrics

1:45 p.m. - 3:15 p.m., Barcelona

Chair: Mattia Rizzi (Lausanne), Daniel Surbek (Bern)

State of the Art: Child with Haemophilia; from pregnancy to birth

Susan Halimeh, Duisburg
2
Differences in the coagulation profile in women with mild and severe eclampsia

E. Lefkou^{1, 2}, A. Rousseau³, P. Vandreden^{3, 2}, L. Papageorgiou², G. Gerotziafas², Presenter: G. Gerotziafas² (¹Thessaloniki, ²Paris, ³Gennevilliers)
3
Acquired von Willebrand Syndrom (avWS) Typ 2 in children with severe pulmonary arterial hypertension (PAH)

I. Wieland, K.-A. Lambeck, G. Hansmann, Presenter: I. Wieland (Hannover)
4
Human Fibrinogen Concentrate for Bleeding Prophylaxis During Surgery in Paediatric Patients with Congenital Fibrinogen Deficiency

C. Djambas Khayat¹, S. D. Lohade², F. D'Souza³, L. S. Gowda⁴, O. Zekavat⁵, I. Kruzhkova⁶, B. Schwartz⁷, C. Solomon⁶, F. Peyvandi⁸, Presenter: C. Djambas Khayat¹ (¹Beirut, ²Pune, ³Bangalore, ⁴Devangere, ⁵Shiraz, ⁶Lachen, ⁷New Jersey, ⁸Milan)
5
The Bacteria-Associated Thrombosis, Thrombophlebitis and LEmierre syndrome (BATTLE) registry: background and rationale.

L. Valerio¹, G. Corsi², T. Sebastian³, S. Barco^{1, 3}, Presenter: L. Valerio¹ (¹Mainz, ²Bologna, ³Zurich)

62 - Oral Communication

Pediatrics & Gynecology-Obstetrics

1:45 p.m. - 3:15 p.m., Barcelona

63 - Oral Communication

Megakaryocytes, Platelets & VWF

1:45 p.m. - 3:15 p.m., Sydney

Chair: Pierre Fontana (Geneva), Chloe James (Bordeaux)

1
Light-induced ion influx triggers megakaryocyte polarization

Y. Zhang, S. Gao, J. Yu-Strzelczyk, H. Kurz, G. Nagel, M. Bender, Presenter: Y. Zhang (Würzburg)
2
Antibodies protect platelet damage by pneumolysin

S. Handtke, K. Jahn, R. Palankar, T. P. Kohler, J. Wesche, S. Hammerschmidt, A. Greinacher, Presenter: S. Handtke (Greifswald)
3
Low adhesion and interaction forces of Myh9 mutant platelets lead to impaired clot retraction and unstable thrombus formation

J. Baumann¹, L. Sachs², Z. Nagy¹, I. Schön³, A. Greinacher², O. Otto², R. Palankar², M. Bender¹, Presenter: J. Baumann¹ (¹Würzburg, ²Greifswald, ³Dublin)
4
Platelets from patients with MYH9 related disorders are mechanically stiffer

L. Sachs¹, J. Baumann², J. Wesche¹, P. Nestler¹, C. Zaninetti¹, L. Lenkeit¹, A. Greinacher¹, M. Bender², O. Otto¹, R. Palankar¹, Presenter: L. Sachs¹ (¹Greifswald, ²Würzburg)
5
Epinephrine enhances platelet aggregation at the expense of procoagulant activity

A. Aliotta, D. Bertaggia Calderara, M. G. Zermatten, L. Alberio, Presenter: A. Aliotta (Lausanne)
6
Phosphorylation and activation of Pannexin-1 upon platelet activation and thrombus formation

L. M. Metz, Presenter: L. M. Metz (Düsseldorf)

63 - Oral Communication

Megakaryocytes, Platelets & VWF

1:45 p.m. - 3:15 p.m., Sydney

64 - Working Group

BDDH-Sitzung

2:00 p.m. - 3:00 p.m., External session

Chair: Günther Kappert (Duisburg), Jürgen Koscielny (Berlin)

Auswirkungen der Gesetzesänderungen in Deutschland auf die Versorgung von Patienten mit hämophilen Gerinnungsstörungen in der täglichen Praxis

1
Aus der Sicht eines Krankenhauses der Maximalversorgung mit einem Hämophiliezentrum

Robert Klamroth, Berlin
2
Aus der Sicht einer Universitätsklinik mit einem Hämophiliezentrum

Georg Goldmann, Bonn
3
Aus der Sicht eines niedergelassenen MVZ mit einem Hämophiliezentrum

Ute Scholz, Leipzig
4
Aus der Sicht einer niedergelassenen Praxis mit einem Hämophiliekoordinationszentrum

Wolfgang Mondorf, Frankfurt am Main
5
Aus der Sicht eines niedergelassenen MVZ mit einem pädiatrischem Hämophiliezentrum

Susan Halimeh, Duisburg

64 - Working Group

BDDH-Sitzung

2:00 p.m. - 3:00 p.m., External session

65 - Working Group

BDDH-MV

3:00 p.m. - 3:30 p.m., External session

Mitgliederversammlung des BDDH e.V. (nicht-öffentlich)

65 - Working Group

BDDH-MV

3:00 p.m. - 3:30 p.m., External session

66 - Plenary

Plenary 3 - Physicians Across Borders

3:30 p.m. - 4:30 p.m., Rome

Chair: Lorenzo Alberio (Lausanne)

Homo cogitans

André-Marie Jerumanis, Lugano
Homo digitalis

Tobias Gantner, Köln

66 - Plenary

Plenary 3 - Physicians Across Borders

3:30 p.m. - 4:30 p.m., Rome

67 - State of the Art

Pediatrics

4:45 p.m. - 6:15 p.m., Rome

Chair: Federica Achini (Zurich), Manuela Albisetti (Zurich)

Treatment of acute venous thromboembolism in children: time for DOACs ?

Mattia Rizzi, Lausanne
Acute recanalization therapies in pediatric ischemic stroke: PRO

Sandra Bigi, Bern
Acute recanalization therapies in pediatric ischemic stroke: CONTRA

Christoph Male, Vienna

67 - State of the Art

Pediatrics

4:45 p.m. - 6:15 p.m., Rome

68 - State of the Art

Cardiology

4:45 p.m. - 6:15 p.m., Barcelona

Chair: Rasha Al-Lamee (London), Marco Valgimigli (Lugano)

Current concepts on the pathophysiology of coronary artery disease

Stéphane Fournier, Lausanne
Aspirin-free treatment strategies in patients with acute coronary syndromes

Roxana Mehran, New York
Combining antiplatelets and anticoagulants in patients with chronic coronary syndrome

Marco Roffi, Geneva

68 - State of the Art

Cardiology

4:45 p.m. - 6:15 p.m., Barcelona

69 - State of the Art

Procoagulant Platelets

4:45 p.m. - 6:15 p.m., Sydney

Chair: Alessandro Aliotta (Lausanne), Kerstin Jurk (Mainz)

Mechanisms of procoagulant COATed platelet generation

Mikhail Panteleev, Moscow
Platelet mitochondrial dynamics and ischemic stroke

Matthew Rondina, Salt Lake City
How to study platelet procoagulant function

Sofia Ramström, Örebro

69 - State of the Art

Procoagulant Platelets

4:45 p.m. - 6:15 p.m., Sydney

70 - State of the Art

Hemato-oncology B

4:45 p.m. - 6:15 p.m., Lausanne

Chair: Julia Riedl (Vienna), Walter Alfred Wuillemin (Luzern)

Currents concepts on pathophysiology and treatment of BCR-ABL-negative myeloproliferative neoplasms

Sara Meyer, Basel
Prevention and management of thrombosis in BCR-ABL-negative myeloproliferative neoplasms

Anna Falanga, Bergamo
Management of pregnancy in BCR-ABL-negative myeloproliferative neoplasms

Martin Griesshammer, Minden

70 - State of the Art

Hemato-oncology B

4:45 p.m. - 6:15 p.m., Lausanne

71 - State of the Art

New treatments

4:45 p.m. - 6:15 p.m., Seoul

Chair: Florian Langer (Hamburg), Verena Schroeder (Bern)

Emerging new treatments in immune thrombocytopenia

Nichola Cooper, London
Novel platelet targets for anti-thrombotic treatment

Martine Jandrot-Perrus, Paris
Emerging anticoagulant strategies

Jeffrey I. Weitz, Hamilton

71 - State of the Art

New treatments

4:45 p.m. - 6:15 p.m., Seoul

72 - Miscellaneous

GTH Mitgliederversammlung

6:30 p.m. - 8:30 p.m., External session

72 - Miscellaneous

GTH Mitgliederversammlung

6:30 p.m. - 8:30 p.m., External session